8-K
filed January 26, 2023, 6:59 PM ET
ticker IKT
CIK 0001750149
other material
confidence high
sentiment neutral
materiality 0.70
Inhibikase raises ~$10M via registered direct offering and private placement with warrants
Inhibikase Therapeutics, Inc.
- Offering includes 6,744,187 shares/equivalents at $0.86/share in registered direct, plus 4,883,721 in private placement.
- Issued unregistered warrants to purchase up to 11,627,908 shares at $0.75/share, exercisable for 5 years.
- Gross proceeds ~$10M; net proceeds for clinical trials, product development, and working capital.
- Terminated prior at-the-market equity distribution agreement with Piper Sandler (no sales made).
- H.C. Wainwright acted as exclusive placement agent; offering expected to close January 27, 2023.
Key facts
Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Inhibikase Therapeutics, Inc. entered into PIPE Purchase Agreement with the same institutional investor (effective 2023-01-25).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- the same institutional investor
- Effective
- 2023-01-25
Exact text from the filing
The Company also entered into a securities purchase agreement (the “PIPE Purchase Agreement” and, together with the Registered Direct Purchase Agreement, the “Purchase Agreements”) and a registration rights agreement (the “Registration Rights Agreement”) in connection with a concurrent private placement (the “PIPE Private Placement”) with the same institutional investor (the “PIPE Purchaser” and, together with the Registered Direct Purchaser, the “Purchaser”).
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.7
Inhibikase Therapeutics, Inc. entered into Engagement Letter with H.C. Wainwright & Co., LLC.
- Action
- entry
- Agreement
- underwriting
- Counterparty
- H.C. Wainwright & Co., LLC
Exact text from the filing
H.C. Wainwright & Co., LLC (“Wainwright”) acted as the exclusive placement agent for the Offerings. The Company entered into an engagement letter (“Engagement Letter”) with Wainwright for potential financings.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Inhibikase Therapeutics, Inc. entered into Registered Direct Purchase Agreement with an institutional investor (effective 2023-01-25).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- an institutional investor
- Effective
- 2023-01-25
Exact text from the filing
On January 25, 2023, Inhibikase Therapeutics, Inc. (“Company”) entered into a securities purchase agreement (the “Registered Direct Purchase Agreement”) in connection with a registered direct offering (the “Registered Direct Offering”) and concurrent private placement with an institutional investor (the “Registered Direct Purchaser”).
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.